New York University

Thomas M Wisniewski

Fernando Goni

Einar M Sigurdsson

Blas Frangione

Jorge Ghiso

Richard Kascsak

Jose Alejandro Chabalgoity

Daryl Spinner

Henrieta Scholtzova

Wei Zhang

Young-Tae Chang

Daniel H Turnbull

Youssef Zaim Wadghiri

Jaeki Min

Qian Li

Marcin Sadowski

Suying Dang

Allal Boutajangout

Fernando R Goni

The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.

Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides

The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of preventing or treating cerebral amyloidosis and Alzheimer's Disease in a subject by administering to the selected subject an agent that stimulates the innate immune system. In addition, a composition useful for the stimulation of the innate immune system of a subject exhibiting symptoms associated with amyloid deposition is disclosed.

Preventing and treating amyloid-beta deposition by stimulation of innate immunity

The present invention relates to antibodies and binding fragments thereof that bind the &#x3b2;-sheet secondary structure of a pathological monomeric or oligomeric non-fibrillar proteins without binding to the non-toxic, non-pathological forms of these proteins or peptides These antibodies and binding fragments thereof are suitable for the diagnosis, prevention, and treatment of protein conformational disorders including all amyloid diseases.

Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides

The present invention is directed to an anti-prion monoclonal antibody and its use for the treatment of conditions associated with or mediated by proteins or peptides having a toxic oligomeric form. These conditions include, but are not limited to, Alzheimer's disease, frontotemporal dementias, traumatic brain injury, and chronic traumatic encephalopathy.

Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy

The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.

Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins

The invention relates to methods for treating human amyloid disease by administration of modified A&#x3b2; peptide immunogens.

Method for treating amyloid disease

Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuatedhost. The vaccines can be used to prevent or treat prion disease in humans and other mammals.

Mucosal immunization to prevent prion infection

The present invention relates to methods inhibiting tumor metastasis and treating cancer in a subject that involve administering to the subject an antibody which recognizes GPIIIa49-66, under conditions effective to inhibit tumor metastasis and/or treat cancer in the subject.

Humanized single-chain antibody against beta 3 integrin for the treatment and prevention of metastasis

Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration of compounds capable of binding to amyloid-beta (A&#x3b2;) or on dialysis of blood or plasma exchange in order to remove A&#x3b2; peptides from the blood circulation, and/or brain or other affected organs.

Growing community of inventors

Staten Island, NY, United States of America

Thomas M Wisniewski